Idiopathic Pulmonary Fibrosis
A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
PharmacoEconomics. 2017 Apr;35(4):479-491
Authors
Rinciog C, Watkins M, Chang S, Maher TM, LeReun C, Esser D, Diamantopoulos A
Process
An original Markov model was designed to capture the changes in the condition of adults with IPF
Systematic and targeted literature reviews
Regression analyses of phase II clinical data
Advisory panel
Publications in other disease areas
Atrial fibrillation
Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke
Cancer
Societal costs of Er+/Her2- advanced or metastatic breast cancer in post-menopausal women in the United Kingdom
Idiopathic pulmonary fibrosis
The burden of illness of idiopathic pulmonary fibrosis: a comprehensive evidence review
Psoriasis
The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis
Rheumatoid arthritis
Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK
Venous thromboembolism
Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective